The small probe "tracks" cancer cells

It was learned from the Fourth Affiliated Hospital of Harbin Medical University that Professor Shen Baozhong’s topic "Molecular Imaging of Mutated EGFR Highly Selective Probes - Molecular Targeted Therapy Sensitivity Assessment and Treatment Therapeutic Efficacy" was recently awarded the National Nature Prize. The committee focused on funding, and this project is the most cutting-edge medical research project for predicting and monitoring molecular targeted therapeutics. It is one of the two key annual projects in the field of molecular imaging in the National Natural Sciences and Nature Commission.

According to reports, lung cancer is one of the highest incidence of malignant tumors in the world. In the past 10 years, the incidence and mortality of lung cancer in China have continued to increase. The early diagnosis rate of lung cancer is only 15%, and the prognosis is poor. The 5-year survival rate is less than 15%. Molecular targeted therapies have brought ** to the treatment of anti-tumor therapy, especially lung cancer, but the treatment is expensive and much higher than traditional anti-tumor chemotherapy drugs; at the same time, it has very good efficacy for some patients, and the effective rate can reach 80%. However, the efficacy of other patients is very poor, the effect is less than 10%; In addition, the molecular targeted therapy to determine the effectiveness of the drug is very limited, you need to take the material in advance, and not all pathologies can get the exact result; more It is important that the therapeutic effects of applying this molecularly targeted drug cannot be monitored, accurately and accurately monitored in vivo, in real time, and intuitively. The above limitations severely restrict the effectiveness and widespread application of molecularly targeted drugs.

Professor Shen Baozhong, a renowned molecular imaging scientist and doctoral tutor of China, set up a special research group for the key issues facing the clinical application of molecularly targeted drugs, and conducted a study on "Living molecular imaging to screen targeted molecular drug therapies and monitoring and treatment. "Efficacy" study. Its major scientific value and significance lies in the fact that through the research of the project, before the molecular targeted therapy, the molecular targeting probe is used to visually predict and determine the effectiveness of the molecular targeted drug in the living body state; in the process of molecular targeted therapy, Accurately determine the binding rate between molecularly targeted drugs and target sites in real time and accurately monitor the therapeutic efficacy of molecularly targeted drugs, thereby opening up a new method for predicting and monitoring the effects of molecular targeted therapies to avoid the blindness of molecular targeted therapies. Guide the selection of clinical treatment options and precise monitoring of the efficacy.